In this study, we provide evidence that IL-6 may contribute to activation of the Nrf2 pathway, resulting in chemotherapeutic resistance by reducing ROS activity in HNSCC cells. This evidence concerns the gene NFE2L2 and head and neck squamous cell carcinoma.